Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer.
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cisplatin
/ administration & dosage
Female
Humans
Male
Middle Aged
Oxaliplatin
/ administration & dosage
Paclitaxel
/ administration & dosage
Peripheral Nervous System Diseases
/ chemically induced
Retrospective Studies
Stomach Neoplasms
/ drug therapy
Ramucirumab
Cisplatin
Gastric cancer
Oxaliplatin
Paclitaxel
Peripheral neuropathy
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
25
07
2019
accepted:
08
12
2019
pubmed:
20
12
2019
medline:
3
7
2020
entrez:
20
12
2019
Statut:
ppublish
Résumé
Fluoropyrimidine plus platinum, followed by paclitaxel (PTX) plus ramucirumab is a recommended treatment strategy for advanced gastric cancer (AGC). We investigated how peripheral neuropathy (PN), induced by platinum in first-line chemotherapy, affected the tolerability of second-line chemotherapy with PTX (2nd-PTX). The subjects were AGC patients who received second-line chemotherapy with PTX (2nd-PTX) after the failure of platinum-based chemotherapy between March 2015 and June 2018. We retrospectively reviewed PN severity, and dose reduction and/or discontinuation due to PN during 2nd-PTX, and compared the cumulative incidence of grade 2 PN between the two groups according to first-line chemotherapy containing oxaliplatin (L-OHP) or cisplatin (CDDP). The L-OHP and CDDP groups consisted of 50 patients each. PN severity before 2nd-PTX was grade 1/2 in 46/12% of patients in the L-OHP group, and 100/0% in the CDDP group. The worst grades of chemotherapy-induced PN during 2nd-PTX were grades 1/2/3 in 40/34/14% of patients in the L-OHP group, and 36/18/0% in the CDDP group. Median time to grade 2 PN after starting second-PTX was 2.5 months in the L-OHP group and 8.6 months in the CDDP group (hazard ratio 3.34, p = 0.002). The frequencies of a PN-related dose reduction and/or discontinuation of PTX were 18% in the L-OHP group and 8% in the CDDP group (p = 0.234). The severity of PN and tolerability of 2nd-PTX may be affected by first-line chemotherapy with L-OHP or CDDP for AGC.
Sections du résumé
BACKGROUND
BACKGROUND
Fluoropyrimidine plus platinum, followed by paclitaxel (PTX) plus ramucirumab is a recommended treatment strategy for advanced gastric cancer (AGC). We investigated how peripheral neuropathy (PN), induced by platinum in first-line chemotherapy, affected the tolerability of second-line chemotherapy with PTX (2nd-PTX).
METHODS
METHODS
The subjects were AGC patients who received second-line chemotherapy with PTX (2nd-PTX) after the failure of platinum-based chemotherapy between March 2015 and June 2018. We retrospectively reviewed PN severity, and dose reduction and/or discontinuation due to PN during 2nd-PTX, and compared the cumulative incidence of grade 2 PN between the two groups according to first-line chemotherapy containing oxaliplatin (L-OHP) or cisplatin (CDDP).
RESULTS
RESULTS
The L-OHP and CDDP groups consisted of 50 patients each. PN severity before 2nd-PTX was grade 1/2 in 46/12% of patients in the L-OHP group, and 100/0% in the CDDP group. The worst grades of chemotherapy-induced PN during 2nd-PTX were grades 1/2/3 in 40/34/14% of patients in the L-OHP group, and 36/18/0% in the CDDP group. Median time to grade 2 PN after starting second-PTX was 2.5 months in the L-OHP group and 8.6 months in the CDDP group (hazard ratio 3.34, p = 0.002). The frequencies of a PN-related dose reduction and/or discontinuation of PTX were 18% in the L-OHP group and 8% in the CDDP group (p = 0.234).
CONCLUSIONS
CONCLUSIONS
The severity of PN and tolerability of 2nd-PTX may be affected by first-line chemotherapy with L-OHP or CDDP for AGC.
Identifiants
pubmed: 31853798
doi: 10.1007/s10147-019-01598-5
pii: 10.1007/s10147-019-01598-5
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Oxaliplatin
04ZR38536J
Paclitaxel
P88XT4IS4D
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
595-601Références
Cancer. 1992 Jan 1;69(1):203-7
pubmed: 1309303
J Clin Oncol. 2000 Aug;18(16):2938-47
pubmed: 10944126
J Clin Oncol. 2013 Dec 10;31(35):4438-44
pubmed: 24190112
CA Cancer J Clin. 2013 Nov-Dec;63(6):419-37
pubmed: 24590861
Int J Clin Oncol. 2015 Aug;20(4):767-75
pubmed: 25627820
J Clin Oncol. 2015 Oct 20;33(30):3416-22
pubmed: 26282635
J Neurol. 2002 Jan;249(1):9-17
pubmed: 11954874
Ann Oncol. 2015 Jan;26(1):141-8
pubmed: 25316259
Cancer. 1990 Oct 15;66(8):1697-702
pubmed: 2119878
N Engl J Med. 2008 Jan 3;358(1):36-46
pubmed: 18172173
J Clin Oncol. 2014 Apr 1;32(10):997-1005
pubmed: 24297951
Acta Oncol. 2007;46(8):1131-7
pubmed: 17851880
J Clin Oncol. 2008 Mar 20;26(9):1435-42
pubmed: 18349393
Semin Oncol. 2006 Feb;33(1):15-49
pubmed: 16473643
Cancer Treat Rev. 2014 Aug;40(7):872-82
pubmed: 24830939
Cancer. 1988 Jun 1;61(11):2192-5
pubmed: 2835140
Curr Pain Headache Rep. 2009 Aug;13(4):282-7
pubmed: 19586591
J Clin Oncol. 1992 May;10(5):795-803
pubmed: 1569451
Semin Oncol Nurs. 2009 May;25(2 Suppl 1):S8-19
pubmed: 19447319
J Peripher Nerv Syst. 1997;2(4):350-61
pubmed: 10975744
J Natl Cancer Inst. 2009 Dec 2;101(23):1624-32
pubmed: 19920223
Cancer Chemother Pharmacol. 2018 Jun;81(6):981-989
pubmed: 29600386
Cancer. 1984 Oct 1;54(7):1269-75
pubmed: 6088023
Cancer. 2010 May 15;116(10):2322-31
pubmed: 20225230
J Clin Oncol. 2012 May 1;30(13):1513-8
pubmed: 22412140
Cancer Chemother Pharmacol. 2018 Oct;82(4):625-633
pubmed: 30043209
J Clin Oncol. 2002 Jun 1;20(11):2651-7
pubmed: 12039926
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313